Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year Low - Here's Why

Key Points

• Kailera Therapeutics shares fell to a new 52-week low of $16.37, below the 50-day moving average of $19.28, giving the company a market capitalization of roughly $2.17 billion.
• Investor sentiment among analysts remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $42.75, though ratings range from “Strong Buy” to “Sell.”
• The company reported a quarterly loss of $1.09 per share, missing the expected loss of $0.74, while analysts project a full-year loss of $3.89 per share.

Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $16.37 and last traded at $16.56, with a volume of 39516 shares trading hands. The stock had previously closed at $17.17.

Analyst Ratings Changes

A number of research firms have recently weighed in on KLRA. Jefferies Financial Group began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a "buy" rating and a $48.00 target price for the company. William Blair began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an "outperform" rating for the company. Weiss Ratings started coverage on shares of Kailera Therapeutics in a research report on Friday, August 14th. They issued a "sell (d)" rating on the stock. TD Cowen initiated coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set a "buy" rating and a $57.00 target price for the company. Finally, Evercore initiated coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an "outperform" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.75.

Kailera Therapeutics Stock Performance

The firm's 50 day moving average price is $19.28. The company has a market capitalization of $2.17 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). As a group, equities analysts expect that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Kailera Therapeutics in the 2nd quarter worth approximately $113,923,000. Wellington Management Group LLP bought a new stake in Kailera Therapeutics in the second quarter worth $64,308,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Kailera Therapeutics in the second quarter worth $24,233,000. Finally, California State Teachers Retirement System purchased a new stake in shares of Kailera Therapeutics in the second quarter worth $309,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source